Antimicrobial resistance patterns of isolated bacteria at Bukoba Regional Referral Hospital in Patients attended from 2019 to 2023 Authors: Eustadius Kamugisha Felician, Tatu Ibrahimu, Sophia Mosha, Juma Kayenzi, George Mosha, Welington Mosses, Levi Minani, Vaileth Mkebezi, George Milambo, Jeremiah Seni, Museleta Nyakiroto Published: 2026 ABSTRACT BackgroundAntimicrobial resistance (AMR) has emerged as a global public health concern, increasing morbidity, mortality, and healthcare costs. Limited surveillance data exist from regional referral hospitals in Tanzania, including Bukoba Regional Referral Hospital (BRRH). Understanding local AMR patterns is essential to guide empirical therapy and inform infection prevention and control strategies. This study aimed to determine the patterns, trends, and factors associated with AMR among bacterial isolates at BRRH between 2019 and 2023.MethodologyA retrospective cross-sectional study was conducted using laboratory records and patient files from Bukoba Regional Referral Hospital between January 2019 and December 2023. Clinical specimens were cultured, bacterial isolates identified using standard microbiological procedures, and antimicrobial susceptibility testing performed using the Kirby–Bauer disk diffusion method according to CLSI 2024 guidelines. Chi-square test was used to assess associations between bacterial isolates and prescribed antimicrobial agents, with statistical significance considered at P < 0.05.ResultsA total of 1,680 specimens were processed during the observation period, the proportion of specimens yielding pathogenic bacterial growth was 297 (17.7%) and 15 (0.9%) of culture samples were discarded due to contamination. The median age of patients was 28 years, with 58% female. Urine 110 (36.9%), pus 99 (33.2%), and stool 76 (25.5%) were the most common samples. Escherichia coli 60 (76.9%), Staphylococcus aureus 32 (86.5%), and Salmonella typhi 63 (100%) were the predominant isolates from urine, pus and stool samples respectively. E. coli showed high resistance to azithromycin (95.0%) and ampicillin (84.4%); S. aureus and coagulase-negative Staphylococci exhibited 100% and 90% resistance to penicillin, respectively. High levels of resistance to commonly used antimicrobial agents on Azithromycin 60 (88.2%), Ceftriaxone 118 (84.3%) and Ampicillin 82 (83.7%) were observed where 17.4% of patients were not prescribed antimicrobial agents despite culture positivity, while mismatches between susceptibility results and prescriptions were common.ConclusionThis study demonstrates a high prevalence of antimicrobial resistance among commonly isolated bacterial pathogens at Bukoba Regional Referral Hospital. Routine development of local antibiograms, strengthening antimicrobial stewardship programs, promoting rational antibiotic prescribing, and enhancing IPC practices are urgently needed to combat AMR at BRRH and similar settings. Introduction Antimicrobial-resistant bacteria that are commonly associated with health care cause a substantial health burden. Updated national estimates for this group of pathogens are needed to inform public health action and for the establishment of hospital local antibiograms [1]. Recently, antimicrobial resistance has been increasing worldwide, and some bacteria are virulent and capable of acquiring multidrug resistance to antimicrobials [2]. For example, Escherichia coli is a Gram-negative bacterium that can generate a large spectrum of beta-lactam enzymes, making it resistant to most beta-lactam antimicrobial agents [3]. Rates of antimicrobial resistance vary according to geographic locations, and they are directly proportional to the use and misuse of antimicrobials [4]. The World Health Organization (WHO) reported that in 2019, nearly 4.95 million deaths were associated with bacterial AMR globally, including 1.27 million deaths directly caused by resistant infections, with sub-Saharan Africa among the most affected regions [1–3]. In East Africa and Tanzania specifically, the spread of resistant pathogens such as Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus has been driven by factors including irrational antibiotic use, limited laboratory surveillance, and inadequate infection prevention and control practices [1–4]. Knowledge of the epidemiology of bacterial infections and antimicrobial susceptibility patterns is essential for guiding empirical treatment, improving antimicrobial stewardship, and strengthening infection prevention and control practices [5]. The spectra of bacteria causing infections and their susceptibility patterns have been found to differ from one setting to another, a fact which highlights the importance of having local surveillance data for planning and implementing infection prevention and control (IPC) measures [6–8]. Infections due to multidrug-resistant isolates are associated with increased morbidity and mortality [9, 10]. The emergence of these multidrug-resistant clones, coupled with the introduction of expensive and last resort antimicrobial agents such as carbapenems and vancomycin, pose a great challenge in combating AMR at Bukoba RRH and in developing countries at large. Inappropriate use of antimicrobials is likely to accelerate the spread of AMR, which has clinical and cost implications for patients, communities and the healthcare system [11, 12]. High income countries including the United States, have managed to decrease the burden of HCAIs by 30% through effective implementation of surveillance systems [13]. A study conducted in a teaching hospital in Nigeria, showed the reduction of HCAIs rates from 5.8 to 2.8% in 2003 and 2006 respectively through the implementation of an effective infection control program [14]. The development of national monitoring systems is an essential part of national action plans for AMR, as clearly stipulated in the Global Action Plan and the Tanzanian National Action Plan on AMR was among the different interventions which has been put in place in Tanzania through the Ministry of Health to address the problem, including the establishment of antimicrobial stewardship programs [1, 15, 16]. Available data on healthcare-associated infections (HCAIs) and antimicrobial resistance (AMR) patterns from regional referral hospitals in many African countries, including Tanzania, remain limited, highlighting the need for strengthened surveillance systems and facility-specific AMR reporting [17–19]. Multidrug resistance (MDR) occurs when bacteria become resistant to at least one antimicrobial agent in three or more antibiotic classes, making infections increasingly difficult to treat. In this study, MDR was notably observed among common pathogens such as Escherichia coli, Klebsiella spp., and Staphylococcus aureus, which showed high resistance to several routinely used antibiotics including ampicillin, ceftriaxone, and azithromycin. The emergence of these resistant organisms may be associated with inappropriate antibiotic use, inadequate antimicrobial stewardship, and weak infection prevention and control practices, highlighting the need for continuous AMR surveillance and rational antimicrobial use [12, 17, 19, 22]. According to the Tanzanian Standard Treatment Guidelines (STG/NEMLIT 2021), the recommended treatment for the predominant bacterial isolates identified in this study depended on the type and severity of infection. Different interventions were put in place in Tanzania through MoH to address the problem, including the establishment of antimicrobial stewardship programs, sustainability of antimicrobial resistance interventions, Antimicrobial resistance focal point, the establishment of national AMR secretariat, establishment of the multi-sectorial coordinating committee, roles and responsibilities of the national AMR secretariat, establishment of multi-Sectorial technical working groups, revitalizing and strengthening medicines and therapeutic committee and quality improvement teams [12, 16, 20–22]. There are scarce data on the antimicrobial resistance patterns of isolated bacteria at Bukoba Regional Referral Hospital among outpatients and inpatients. Accordingly, this study sought to assess the antimicrobial resistance patterns of bacterial isolates among all patients at Bukoba Regional Referral Hospital from 2019 to 2023. Methods Study design and setting This was a retrospective cross-sectional study conducted at Bukoba Regional Referral Hospital (BRRH) in Kagera Region, Tanzania. The study involved review of laboratory records and patient files for clinical specimens processed for culture and antimicrobial susceptibility testing between January 2019 and December 2023. This facility is located at Bukoba municipality in the Kagera region, which is among the lake zone regions. Kagera, specifically Bukoba RRH is among the regional referral hospitals with no publication on AMR from our data. This facility provides culture and sensitivity services through the hospital laboratory. The laboratory has been accredited by SADCAS with accreditation number MED 092 and received microbiology EQA samples from the Tanzania National Public Health Laboratory (NPHL), with an average performance score over 80%. The study population was a patient dataset with culture results collected at Bukoba Regional Referral Hospital from January 2019 to December 2023. This included all patients’ data regardless of their age category. Sample size determination Due to the retrospective design of the study, exhaustive sampling was used whereby all available records with documented culture and antimicrobial susceptibility testing results from January 2019 to December 2023 were included. This approach minimized selection bias and improved representation of antimicrobial resistance patterns at Bukoba RRH. A total of 1,680 clinical specimens met the inclusion criteria and were analyzed. The sample size for the study extracted was 1680 culture results retrieved from afyacare, GoTHOMIS and patient files based on the laboratory register and microbiology data sheet. This is the total number of samples received and processed at the laboratory during the study period. This sample size was based on the total sample of culture and sensitivity received at the Bukoba RRH laboratory per year, as the laboratory can process more than 350 culture samples per year [23]. A total of 1680 records was selected for data extraction. Data were extracted using a structured data extraction checklist developed in Microsoft Excel from Afyacare, GoTHOMIS, laboratory registers, and patient files. The information extracted from the laboratory through Afyacare and GoTHOMIS system included the sex and age of patients, the type of clinical sample cultured, the name of bacteria isolated, names of antimicrobial agents used for susceptibility testing, and the susceptibility results recorded in the laboratory report, diagnosis, prescribed antimicrobial agents and signs and symptoms of the patients attended at Bukoba RRH. The data of bacteria profile, AST patterns and MDR was obtained from laboratory registers and both hospital systems by laboratory personnel. Records were selected using a retrospective review approach based on the availability of documented culture and sensitivity results during the study period. Only records with complete demographic information and microbiological results were included in the analysis, while incomplete records were excluded. Specimen collection, processing and identification of bacteria Standardized procedures for the collection, storage, and transportation of clinical specimens were strictly followed, and specimens were collected from surgical wards, medical wards, pediatric wards, maternity wards, obstetrics and gynecology wards and clinics. Clinical specimens including urine, stool, pus/wound swabs, sputum, blood, cerebrospinal fluid, body fluids, ear/eye discharge, and tracheal aspirates were processed using standard microbiological procedures following CLSI 2024 guidelines. Samples were inoculated onto appropriate culture media depending on specimen type, including Blood agar, MacConkey agar, and Chocolate agar for routine bacterial isolation, while selective media such as Xylose Lysine Deoxycholate (XLD) agar and Salmonella-Shigella (SS) agar were used for stool specimens. Urine samples were cultured using Cystine Lactose Electrolyte Deficient (CLED) agar where applicable. Inoculated plates were incubated aerobically at 35–37 °C for 18–24 h, while Chocolate agar plates were incubated in a 5–10% CO₂-enriched atmosphere. Negative cultures were further incubated for up to 48 h before being reported as no growth. Bacterial identification was performed using colony morphology, Gram staining characteristics, and standard biochemical tests according to CLSI-recommended procedures and laboratory SOPs. Antimicrobial susceptibility testing (AST) was conducted using the Kirby–Bauer disk diffusion technique on Mueller–Hinton agar according to CLSI 2024 guidelines. Standardized bacterial suspensions equivalent to 0.5 McFarland standard were inoculated onto the agar surface followed by application of antimicrobial discs. Quality control was ensured using reference strains including Escherichia coli ATCC 25,922 and Staphylococcus aureus ATCC 25,923. We included patient culture results attended at Bukoba Regional Referral Hospital from January 2019 to December 2023. Patients result with incompletely filled-in microbiological laboratory form for both demographic data and culture results were excluded from the study. Data management and analysis Antimicrobial resistance (AMR) patterns were termed as dependent variables and this included a description of the resistance patterns for all isolates after antibiotic susceptibility testing. Socio-demographic factors and other related factors were termed as independent variables. The information extracted included the sex and age of patients, the type of clinical sample cultured, the name of bacteria isolated, the names of antimicrobial agents used for susceptibility testing, and the susceptibility results recorded in the laboratory report. Data cleaning and analysis was performed using STATA version 15 StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC. Preliminary data exploration was done to check for missing values, duplications, and unusual observations before analysis. Missing values on the outcomes was dropped from the analysis. Descriptive statistics were used to summarize demographic characteristics, bacterial isolates, and antimicrobial resistance patterns using frequencies and percentages. Inferential analysis was performed using Chi-square tests to assess associations between categorical variables where appropriate. A p-value of less than 0.05 was considered statistically significant, and 95% confidence intervals (CIs) were reported where applicable. The trend of several bacteria isolated per year was presented, which also included the trend of antimicrobial resistance of isolated bacteria per year. AMR was determined over a specific bacterium isolated and MDR was determined to examine the proportion of MDR for all bacteria isolated. Finally, the comparison was made on prescribed antimicrobial agents over susceptible antimicrobial agents from the laboratory. Results Demographic characteristics of patients We processed a total of 1,680 specimens during the observation period, but only 297 (17.7%) were culture-positive and 15 (0.9%) were discarded due to contamination. The patients’ median (IQR) age was 28 (12–44) years and female constituted 173 (58.0%) of the participants. Furthermore, the majority of the patients were outpatient 152 (51.0%) and among positive culture results majority of the sample were urine samples. Additionally, 85 (58.2%) of in patients were from medical wards. From the year 2019 to 2023 a total of 297 bacteria were isolated and regarded as culture positive results, where the year 2023 contributed majority of the culture positive results by 123 (41.4%) of all isolates. Most bacterial isolates were recovered from urine specimens (Table 1), while the trend of bacterial isolation across the study years is presented in Fig. 1. Table 1Demographic characteristics of the study participantsVariables (N = 297)Frequency (N)Percentage (%) Age category (years) Mean age 36.5+- 19.80–4903.05–153411.416–4916254.450 and above9331.2 Sex Male12542.0Female17358.0 Patient category Outpatient15251.0In-patient14649.0In-patient department (N = 146)Medical8558.2Obs & gyn3926.7Surgical138.9Pediatric96.2 Specimen type Urine11036.9Pus9933.2Stool7625.5Others124.4 Total 297 100 Table 1Demographic characteristics of the study participantsVariables (N = 297)Frequency (N)Percentage (%) Age category (years) Mean age 36.5+- 19.80–4903.05–153411.416–4916254.450 and above9331.2 Sex Male12542.0Female17358.0 Patient category Outpatient15251.0In-patient14649.0In-patient department (N = 146)Medical8558.2Obs & gyn3926.7Surgical138.9Pediatric96.2 Specimen type Urine11036.9Pus9933.2Stool7625.5Others124.4 Total 297 100 Demographic characteristics of the study participants Fig. 1Trend on number of bacteria isolated from 2019 to 2023 at Bukoba Regional Referral Hospital Trend on number of bacteria isolated from 2019 to 2023 at Bukoba Regional Referral Hospital Distribution of bacteria isolated by clinical specimen Table 2 shows distribution of bacteria isolated by clinical specimen. Majority of the specimen collected were urine, pus and stool samples contributed about 110 (36.9%), 99 (33.2%) and 76 (25.5%) of all culture positive samples respectively. From urine samples majority of bacteria isolated were Escherichia coli 60 (76.9%) and 10 (50.0%) for Klebsiella spp. Among pus samples majority of bacteria isolated were Staphylococcus aureus 32 (86.5%) and 15 (19.2%) for Escherichia coli, where 63 (100%) of Salmonella typhi were isolated from stool samples. There was significant association between isolated bacteria and type of clinical specimen with X²=464.92 and P ≤ 0.001. Table 2Distribution of identified bacterial isolates by clinical specimenIsolate type N Specimen TypePus (%)Stool (%)Urine (%)Others (%)X², P-ValueAcinetobacter spp42 (50.0)0 (0.0)2 (50)0 (0.0)X²=464.92 P = 0.0000Citrobacter spp126 (50.0)0 (0.0)5 (41.7)1 (8.3) Escherichia coli 7815 (19. 2)0 (0.0)60 (76.9)3 (3.9)Klebsiella spp2010 (50.0)0 (0.0)10 (50.0)0 (0.0)Proteus spp144 (28.6)0 (0.0)8 (57.1)2 (14.3) Pseudomonas aeruginosa 168 (50.0)0 (0.0)8 (50.0)0 (0.0) Salmonella typhi 630 (0.0)63 (100.0)0 (0.0)0 (0.0) Salmonella tyhimurium 50 (0.0)5 (100.0)0 (0.0)0 (0.0)Salmonella spp60 (0.0)6 (100.0)0 (0.0)0 (0.0)Serratia spp124 (33.3)0 (0.0)8 (66.7)0 (0.0) Staphylococcus aureus 3732 (86.5)0 (0.0)4 (10.8)1 (2.7)Staphylococcus spp1915 (79.0)0 (0.0)2 (10.5)2 (10.5)Enterobacter spp32 (66.7)0 (0.0)1 (33.3)0 (0.0)Shigella spp30 (0.0)2 (66.7)1 (33.3)0 (0.0) Streptococcus pneumoniae 20 (0.0)0 (0.0)0 (0.0)2 (100.0) Neisseria gonorrhoeae 20 (0.0)0 (0.0)1 (50.0)1 (50.0) Streptococcus viridans 11 (100.0)0 (0.0)0 (0.0)0 (0.0)Haemophilus spp10 (0.0)0 (0.0)0 (0.0)1 (100.0) Total 297 99 (33.2) 76 (25.5) 110 (36.9) 13 (4.4) Table 2Distribution of identified bacterial isolates by clinical specimenIsolate type N Specimen TypePus (%)Stool (%)Urine (%)Others (%)X², P-ValueAcinetobacter spp42 (50.0)0 (0.0)2 (50)0 (0.0)X²=464.92 P = 0.0000Citrobacter spp126 (50.0)0 (0.0)5 (41.7)1 (8.3) Escherichia coli 7815 (19. 2)0 (0.0)60 (76.9)3 (3.9)Klebsiella spp2010 (50.0)0 (0.0)10 (50.0)0 (0.0)Proteus spp144 (28.6)0 (0.0)8 (57.1)2 (14.3) Pseudomonas aeruginosa 168 (50.0)0 (0.0)8 (50.0)0 (0.0) Salmonella typhi 630 (0.0)63 (100.0)0 (0.0)0 (0.0) Salmonella tyhimurium 50 (0.0)5 (100.0)0 (0.0)0 (0.0)Salmonella spp60 (0.0)6 (100.0)0 (0.0)0 (0.0)Serratia spp124 (33.3)0 (0.0)8 (66.7)0 (0.0) Staphylococcus aureus 3732 (86.5)0 (0.0)4 (10.8)1 (2.7)Staphylococcus spp1915 (79.0)0 (0.0)2 (10.5)2 (10.5)Enterobacter spp32 (66.7)0 (0.0)1 (33.3)0 (0.0)Shigella spp30 (0.0)2 (66.7)1 (33.3)0 (0.0) Streptococcus pneumoniae 20 (0.0)0 (0.0)0 (0.0)2 (100.0) Neisseria gonorrhoeae 20 (0.0)0 (0.0)1 (50.0)1 (50.0) Streptococcus viridans 11 (100.0)0 (0.0)0 (0.0)0 (0.0)Haemophilus spp10 (0.0)0 (0.0)0 (0.0)1 (100.0) Total 297 99 (33.2) 76 (25.5) 110 (36.9) 13 (4.4) Distribution of identified bacterial isolates by clinical specimen Distribution of bacteria isolated by hospital departments Table 3 present bacterial isolated across different departments. The majority of the isolated bacteria were from outpatient department 152 (51.0%) and the most contributing isolates were Salmonella Typhi, which accounted for 59 (88.9%) of all outpatients isolated. The medical department was the second, which contributed 85 (28.5%) of all bacteria isolates and the majority of isolated bacteria was Escherichia coli, with 35 (44.9%) of isolates from the medical department. There was a significant association between isolated bacteria and the department with X²=136.14 and P ≤ 0.001. Table 3Bacterial isolates distribution by departmentIsolates N DepartmentX², P-valueMedicalObsy&GynPediatricSurgicalOutpatient Acinetobacter spp 41 (25.0)1 (25.0)0 (0.0)0 (0.0)2 (50.0)X²=136.14 P = 0.0000 Citrobacter spp 123 (25.0)6 (50.0)0 (0.0)1 (8.3)2 (16.7) Escherichia coli 7835 (44.9)4 (5.1)3 (3.9)3 (3.9)33 (42.3) Haemophilus 10 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (100.0) Klebsiella spp 204 (20.0)7 (35.0)0 (0.0)1 (5.0)8 (40.0) Neisseria gonorrhoeae 21 (50.0)0 (0.0)0 (0.0)0 (0.0)1 (50.0) Proteus spp 144 (28.6)2 (14.3)0 (0.0)1 (7.1)7 (50.0) Pseudomonas aeruginosa 165 (31.3)2 (12.5)0 (0.0)1 (6.3)8 (50.0) Streptococcus viridans 10 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (100.0) Salmonella Typhi 637 (11.1)0 (0.0)0 (0.0)0 (0.0)59 (88.9) Salmonella Typhimurium 55 (100.0) Salmonella spp 60 (0.0)0 (0.0)0 (0.0)1 (16.7)5 (83.3) Serratia spp 123 (25.0)2 (16.7)0 (0.0)1 (8.3)6 (50.0) Shigella spp 32 (66.7)0 (0.0)1 (33.3)0 (0.000 (0.0) Staphylococcus aureus 3715 (40.5)8 (21.6)4 (10.8)2 (5.4)8 (21.6) Staphylococcus spp 192 (10.5)6 (31.6)1 (5.3)2 (10.5)8 (42.1) Streptococcus pneumoniae 21 (50.0)0 (0.0)0 (0.0)0 (0.0)1 (50.0) Enterobacter spp 32 (66.7)1 (33.3)0 (0.0)0 (0.0)0 (0.0) Total 297 85 (28.5) 39 (13.1) 9 (3.0) 13 (4.4) 152 (51.0) Table 3Bacterial isolates distribution by departmentIsolates N DepartmentX², P-valueMedicalObsy&GynPediatricSurgicalOutpatient Acinetobacter spp 41 (25.0)1 (25.0)0 (0.0)0 (0.0)2 (50.0)X²=136.14 P = 0.0000 Citrobacter spp 123 (25.0)6 (50.0)0 (0.0)1 (8.3)2 (16.7) Escherichia coli 7835 (44.9)4 (5.1)3 (3.9)3 (3.9)33 (42.3) Haemophilus 10 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (100.0) Klebsiella spp 204 (20.0)7 (35.0)0 (0.0)1 (5.0)8 (40.0) Neisseria gonorrhoeae 21 (50.0)0 (0.0)0 (0.0)0 (0.0)1 (50.0) Proteus spp 144 (28.6)2 (14.3)0 (0.0)1 (7.1)7 (50.0) Pseudomonas aeruginosa 165 (31.3)2 (12.5)0 (0.0)1 (6.3)8 (50.0) Streptococcus viridans 10 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (100.0) Salmonella Typhi 637 (11.1)0 (0.0)0 (0.0)0 (0.0)59 (88.9) Salmonella Typhimurium 55 (100.0) Salmonella spp 60 (0.0)0 (0.0)0 (0.0)1 (16.7)5 (83.3) Serratia spp 123 (25.0)2 (16.7)0 (0.0)1 (8.3)6 (50.0) Shigella spp 32 (66.7)0 (0.0)1 (33.3)0 (0.000 (0.0) Staphylococcus aureus 3715 (40.5)8 (21.6)4 (10.8)2 (5.4)8 (21.6) Staphylococcus spp 192 (10.5)6 (31.6)1 (5.3)2 (10.5)8 (42.1) Streptococcus pneumoniae 21 (50.0)0 (0.0)0 (0.0)0 (0.0)1 (50.0) Enterobacter spp 32 (66.7)1 (33.3)0 (0.0)0 (0.0)0 (0.0) Total 297 85 (28.5) 39 (13.1) 9 (3.0) 13 (4.4) 152 (51.0) Bacterial isolates distribution by department Antimicrobial-resistant pattern of isolated bacteria E. coli exhibited high resistance to azithromycin (95.0%), ampicillin (84.4%), and piperacillin (71.4%), but lower resistance to amoxicillin (20.7%) and oxacillin (37.9%). Proteus spp and Pseudomonas aeruginosa showed 100% resistance to several antimicrobial agents. S. aureus and coagulase-negative Staphylococci (CoNS) were highly resistant to penicillin (100% and 90%, respectively), yet sensitive to nitrofurantoin and ciprofloxacin. Resistance to third-generation cephalosporins (e.g., ceftriaxone, ceftazidime) was common among Gram-negative bacteria. Table 4 & 5. Table 4Antimicrobial resistance pattern of bacterial isolates tested in the laboratoriesIsolatesAMK (%)N = 74AMX (%)N = 49CIP (%)N = 85AMP (%)N = 98AZM (%)N = 68OX (%)N = 80TZP (%)N = 68 Acinetobacter spp 2 (100.0)2 (66.7)2 (50.0)3 (75.0)2 (66.7)1 (50.0) Citrobacter spp 1 (50.0)0 (0.0)6 (100.0)5 (100.0)2 (66.7)2 (50.0) Escherichia coli 26 (65.0)6 (20.7)7 (58.3)27 (84.4)19 (95.0)11 (37.9)15 (71.4) Haemophilus 0 (0.0)1 (100.0)1 (100) Klebsiella spp 6 (85.7)3 (75.0)2 (50.0)10 (90.9)7 (100.0)2 (50.0)6 (66.7) Neisseria gonorrhoeae 1 (100.0)1 (100.0)2 (100.0)0 (0.0)1 (100) Proteus spp 5 (62.5)1 (20.0)0 (0.0)9 (90.0)7 (87.5)1 (12.5)7 (100) Pseudomonas aeruginosa 2 (100.0)2 (100.0)1 (14.3)4 (100.0)3 (100.0)3 (60.0)3 (75.0) Streptococcus viridans 0 (0.0)0 (0.0) Salmonella Typhi 2 (66.7)14 (82.4)4 (100.0)1 (100.0) Salmonella Typhimurium 0 (0.0)1 (100.0) Salmonella spp 0 (0.0)2 (66.7) Serratia spp 6 (85.7)2 (66.7)0 (0.0)4 (80.0)1 (100.0)1 (25.0)3 (60.0) Shigella spp 1 (100.0)0 (0.0)0 (0.0) Staphylococcus aureus 1 (50.0)0 (0.0)0 (0.0)20 (58.8)7 (70.0)6 (75.0)6 (54.6) Staphylococcus spp 1 (100.0)1 (100.0)3 (50.0)11 (84.6)1 (50.0) Streptococcus pneumoniae 0 (0.0)0 (0.0) Enterobacter spp 0 (0.0)1 (100.0)1 (100.0)0 (0.0)1 (100) Total 52 (70.3) 17 (34.7) 2 (20.0) 82 (83.7) 60 (88.2) 39 (48.8) 47 (69.1) Table 4Antimicrobial resistance pattern of bacterial isolates tested in the laboratoriesIsolatesAMK (%)N = 74AMX (%)N = 49CIP (%)N = 85AMP (%)N = 98AZM (%)N = 68OX (%)N = 80TZP (%)N = 68 Acinetobacter spp 2 (100.0)2 (66.7)2 (50.0)3 (75.0)2 (66.7)1 (50.0) Citrobacter spp 1 (50.0)0 (0.0)6 (100.0)5 (100.0)2 (66.7)2 (50.0) Escherichia coli 26 (65.0)6 (20.7)7 (58.3)27 (84.4)19 (95.0)11 (37.9)15 (71.4) Haemophilus 0 (0.0)1 (100.0)1 (100) Klebsiella spp 6 (85.7)3 (75.0)2 (50.0)10 (90.9)7 (100.0)2 (50.0)6 (66.7) Neisseria gonorrhoeae 1 (100.0)1 (100.0)2 (100.0)0 (0.0)1 (100) Proteus spp 5 (62.5)1 (20.0)0 (0.0)9 (90.0)7 (87.5)1 (12.5)7 (100) Pseudomonas aeruginosa 2 (100.0)2 (100.0)1 (14.3)4 (100.0)3 (100.0)3 (60.0)3 (75.0) Streptococcus viridans 0 (0.0)0 (0.0) Salmonella Typhi 2 (66.7)14 (82.4)4 (100.0)1 (100.0) Salmonella Typhimurium 0 (0.0)1 (100.0) Salmonella spp 0 (0.0)2 (66.7) Serratia spp 6 (85.7)2 (66.7)0 (0.0)4 (80.0)1 (100.0)1 (25.0)3 (60.0) Shigella spp 1 (100.0)0 (0.0)0 (0.0) Staphylococcus aureus 1 (50.0)0 (0.0)0 (0.0)20 (58.8)7 (70.0)6 (75.0)6 (54.6) Staphylococcus spp 1 (100.0)1 (100.0)3 (50.0)11 (84.6)1 (50.0) Streptococcus pneumoniae 0 (0.0)0 (0.0) Enterobacter spp 0 (0.0)1 (100.0)1 (100.0)0 (0.0)1 (100) Total 52 (70.3) 17 (34.7) 2 (20.0) 82 (83.7) 60 (88.2) 39 (48.8) 47 (69.1) Antimicrobial resistance pattern of bacterial isolates tested in the laboratories Table 5Antimicrobial resistant pattern of bacterial isolates tested in the laboratoriesIsolatesCTX (%)N = 95FOX (%)N = 182CRO (%)N = 140DOX (%)N = 164TCY (%)N = 118CFM (%)N = 71 Acinetobacter spp 1 (100.0)2 (66.7)1 (100)2 (50.0)2 (66.7)2 (66.7) Citrobacter spp 0 (0.0)3 (50.0)5 (83.3)5 (83.3)8 (100)5 (100.0) Escherichia coli 3 (30.0)30 (52.6)43 (89.6)24 (52.2)33 (82.5)17 (56.7) Klebsiella spp 2 (50.0)9 (64.3)12 (80.0)7 (53.9)12 (85.7)9 (69.2) Neisseria gonorrhoeae 1 (100)1 (100)1 (50.0)1 (100)1 (50.0) Proteus spp 1 (100)5 (45.5)6 (100)8 (66.7)8 (100)3 (37.5) Pseudomonas aeruginosa 5 (71.4)2 (100)4 (57.1)4 (100)2 (100.0) Streptococcus viridans 0 (0.0)0 (0.0) Salmonella Typhi 8 (13.8)9 (15.0)24 (80.0)13 (22.4)1 (100.0) Salmonella Typhimurium 0 (0.0) Salmonella spp 0 (0.0) Serratia spp 1 (50.0)5 (55.6)2 (50.0)4 (50.0)6 (85.7)2 (40.0) Shigella spp 1 (100)1 (100)0 (0.0) Staphylococcus aureus 5 (31.3)4 (40.0)19 (86.4)2 (40.0)5 (27.8) Staphylococcus spp 0 (0.0)5 (62.5) Streptococcus pneumoniae 0 (0.0)1 (50.0) Enterobacter spp 0 (0.0)2 (66.7)1 (100)3 (100)1 (50.0) Total 21 (22.1) 74 (40.1) 118 (84.3) 71 (43.3) 88 (74.6) 43 (60.6) Table 5Antimicrobial resistant pattern of bacterial isolates tested in the laboratoriesIsolatesCTX (%)N = 95FOX (%)N = 182CRO (%)N = 140DOX (%)N = 164TCY (%)N = 118CFM (%)N = 71 Acinetobacter spp 1 (100.0)2 (66.7)1 (100)2 (50.0)2 (66.7)2 (66.7) Citrobacter spp 0 (0.0)3 (50.0)5 (83.3)5 (83.3)8 (100)5 (100.0) Escherichia coli 3 (30.0)30 (52.6)43 (89.6)24 (52.2)33 (82.5)17 (56.7) Klebsiella spp 2 (50.0)9 (64.3)12 (80.0)7 (53.9)12 (85.7)9 (69.2) Neisseria gonorrhoeae 1 (100)1 (100)1 (50.0)1 (100)1 (50.0) Proteus spp 1 (100)5 (45.5)6 (100)8 (66.7)8 (100)3 (37.5) Pseudomonas aeruginosa 5 (71.4)2 (100)4 (57.1)4 (100)2 (100.0) Streptococcus viridans 0 (0.0)0 (0.0) Salmonella Typhi 8 (13.8)9 (15.0)24 (80.0)13 (22.4)1 (100.0) Salmonella Typhimurium 0 (0.0) Salmonella spp 0 (0.0) Serratia spp 1 (50.0)5 (55.6)2 (50.0)4 (50.0)6 (85.7)2 (40.0) Shigella spp 1 (100)1 (100)0 (0.0) Staphylococcus aureus 5 (31.3)4 (40.0)19 (86.4)2 (40.0)5 (27.8) Staphylococcus spp 0 (0.0)5 (62.5) Streptococcus pneumoniae 0 (0.0)1 (50.0) Enterobacter spp 0 (0.0)2 (66.7)1 (100)3 (100)1 (50.0) Total 21 (22.1) 74 (40.1) 118 (84.3) 71 (43.3) 88 (74.6) 43 (60.6) Antimicrobial resistant pattern of bacterial isolates tested in the laboratories Proportion of isolated bacteria with pre-scribed antimicrobial agents There were mismatches between susceptibility patterns and antimicrobial agents prescribed as presented in Table 6. For instance, 40.6% of E. coli cases were prescribed Ciprofloxacin, despite high resistance to it in earlier tables. A large number of isolates (17.4%) were from patients not prescribed any antimicrobial agents. There were a significance association between isolated bacteria and pre-scribed antimicrobial agents with (OR = 6.61, 95% CI: 2.20–19.85, P = 0.001). Table 6Proportion of isolated bacteria with pre-scribed antimicrobial agents at Bukoba RHHIsolatesAMC (%)AMP&CLOXAZICROCHLOCIPCOTFLU&AMOXGENTANITOTHERSNO ANTIMICROBIAL AGENTS PRE-SCRIBEDAcinetobacter spp1(33.3)2 (66.7)0(0.0)0 (0.0)0 (0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)Citrobacter spp0(0.0)0 (0.0)0(0.0)0 (0.0)1(25.0)0(0.0)0(0.0)0(0.0)2(50.0)0(0.0)1(25.0)1(25.0) Escherichia coli 3(9.4)2 (6.3)0(0.0)2 (6.3)0 (0.0)13(40.6)2(6.3)2(6.3)0(0.0)3(9.4)5(15.6) Haemophilus Klebsiella spp1(11.1)2 (22.2)0(0.0)0(0.0)0 (0.0)0(0.0)0(0.0)1(11.1)2(22.2)0(0.0)3(33.3) Neisseria gonorrhoeae 0(0.0)0 (0.0)0(0.0)0(0.0)0 (0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)1(100)Proteus spp0(0.0)0 (0.0)0(0.0)0(0.0)0 (0.0)1(16.7)0(0.0)0(0.0)2(33.3)1(16.7)2(33.3) Pseudomonas aeruginosa 0(0.0)0 (0.0)0(0.0)0(0.0)0 (0.0)0(0.0)0(0.0)1(16.7)2(33.3)0(0.0)3(50.0) Streptococcus viridans 0(0.0)1 (100)0(0.0)0(0.0)0 (0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0) Salmonella Typhi 0(0.0)0 (0.0)0(0.0)0(0.0)0 (0.0)1(50.0)1(50.0)0(0.0)0(0.0)0(0.0)0(0.0) Salmonella Typhimurium 0(0.0)0 (0.0)0(0.0)0(0.0)0 (0.0)0(0.0)0(0.0)0(0.0)2(50.0)0(0.0)1(25.0)0(0.0)Salmonella spp0(0.0)0 (0.0)3(75.0)0(0.0)0 (0.0)0(0.0)0(0.0)0(0.0)1(25.0)0(0.0)2(50.0)0(0.0)Serratia spp0(0.0)0 (0.0)0(0.0)1(12.5)0 (0.0)3(37.5)1(12.5)0(0.0)1(12.5)0(0.0)2(25.0)Shigella spp0(0.0)0 (0.0)0(0.0)0(0.0)0 (0.0)0(0.0)0(0.0)0(0.0)0(0.0)1(100)0(0.0) Staphylococcus aureus 1(8.3)5 (41.7)0(0.0)0(0.0)1(8.3)1(8.3)0(0.0)2(16.7)0(0.0)0(0.0)1(8.3)0(0.0)Staphylococcus spp1 (33.3)0(0.0)1(33.3)0 (0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)1(33.3)0(0.0) Streptococcus pneumoniae 1(50.0)0 (0.0)0(0.0)0(0.0)0 (0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)Enterobacter sppTotal7(14.1)13 (13.3)3(3.1)4(4.1)2(2.0)19(19.4)4(4.1)6(6.1)12(12.2)4(4.1)7(4.2)17(17.4)Others (Tetracycline, Vancomycin, Cefixime, Erythromycin, Azithromycin, Chloramphenicol, Clarithromycin) Table 6Proportion of isolated bacteria with pre-scribed antimicrobial agents at Bukoba RHHIsolatesAMC (%)AMP&CLOXAZICROCHLOCIPCOTFLU&AMOXGENTANITOTHERSNO ANTIMICROBIAL AGENTS PRE-SCRIBEDAcinetobacter spp1(33.3)2 (66.7)0(0.0)0 (0.0)0 (0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)Citrobacter spp0(0.0)0 (0.0)0(0.0)0 (0.0)1(25.0)0(0.0)0(0.0)0(0.0)2(50.0)0(0.0)1(25.0)1(25.0) Escherichia coli 3(9.4)2 (6.3)0(0.0)2 (6.3)0 (0.0)13(40.6)2(6.3)2(6.3)0(0.0)3(9.4)5(15.6) Haemophilus Klebsiella spp1(11.1)2 (22.2)0(0.0)0(0.0)0 (0.0)0(0.0)0(0.0)1(11.1)2(22.2)0(0.0)3(33.3) Neisseria gonorrhoeae 0(0.0)0 (0.0)0(0.0)0(0.0)0 (0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)1(100)Proteus spp0(0.0)0 (0.0)0(0.0)0(0.0)0 (0.0)1(16.7)0(0.0)0(0.0)2(33.3)1(16.7)2(33.3) Pseudomonas aeruginosa 0(0.0)0 (0.0)0(0.0)0(0.0)0 (0.0)0(0.0)0(0.0)1(16.7)2(33.3)0(0.0)3(50.0) Streptococcus viridans 0(0.0)1 (100)0(0.0)0(0.0)0 (0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0) Salmonella Typhi 0(0.0)0 (0.0)0(0.0)0(0.0)0 (0.0)1(50.0)1(50.0)0(0.0)0(0.0)0(0.0)0(0.0) Salmonella Typhimurium 0(0.0)0 (0.0)0(0.0)0(0.0)0 (0.0)0(0.0)0(0.0)0(0.0)2(50.0)0(0.0)1(25.0)0(0.0)Salmonella spp0(0.0)0 (0.0)3(75.0)0(0.0)0 (0.0)0(0.0)0(0.0)0(0.0)1(25.0)0(0.0)2(50.0)0(0.0)Serratia spp0(0.0)0 (0.0)0(0.0)1(12.5)0 (0.0)3(37.5)1(12.5)0(0.0)1(12.5)0(0.0)2(25.0)Shigella spp0(0.0)0 (0.0)0(0.0)0(0.0)0 (0.0)0(0.0)0(0.0)0(0.0)0(0.0)1(100)0(0.0) Staphylococcus aureus 1(8.3)5 (41.7)0(0.0)0(0.0)1(8.3)1(8.3)0(0.0)2(16.7)0(0.0)0(0.0)1(8.3)0(0.0)Staphylococcus spp1 (33.3)0(0.0)1(33.3)0 (0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)1(33.3)0(0.0) Streptococcus pneumoniae 1(50.0)0 (0.0)0(0.0)0(0.0)0 (0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)Enterobacter sppTotal7(14.1)13 (13.3)3(3.1)4(4.1)2(2.0)19(19.4)4(4.1)6(6.1)12(12.2)4(4.1)7(4.2)17(17.4)Others (Tetracycline, Vancomycin, Cefixime, Erythromycin, Azithromycin, Chloramphenicol, Clarithromycin) Proportion of isolated bacteria with pre-scribed antimicrobial agents at Bukoba RHH Others (Tetracycline, Vancomycin, Cefixime, Erythromycin, Azithromycin, Chloramphenicol, Clarithromycin) Proportion of isolated bacteria with their corresponding diagnosis at Bukoba RRH Table 7 shows a significant association between bacterial isolates and clinical diagnoses (X² = 161.34, P ≤ 0.001). UTIs (34%) were mainly caused by E. coli (73.8%), followed by Proteus spp and Pseudomonas aeruginosa. Typhoid (15.7%) was strongly linked to Salmonella Typhi and other Salmonella species. Septic wounds (13.8%) were mostly associated with Staphylococcus aureus (40%). Amoebiasis (5.7%) involved Salmonella Typhi, while other diagnoses (30.8%) showed mixed pathogens, mainly S. aureus, S. Typhi, and E. coli. Overall, E. coli dominated UTIs, S. aureus dominated wound infections, and Salmonella species dominated typhoid cases. Table 7Proportions of isolated bacteria with different diagnoses at Bukoba RRH, X²=161.34, P ≤ 0.001Bacteria isolatedDiagnosisAmoebiasisSeptic woundTyphoidUrinary Tract Infection (UTI)Other diagnosisAcinetobacter spp0 (0.0)1 (100)0 (0.0)0 (0.0)0 (0.0)Citrobacter spp0 (0.0)2 (33.3)0 (0.0)3 (50.0)1 (16.7) Escherichia coli 0 (0.0)3 (7.1)0 (0.0)31 (73.8)8 (19.1)Klebsiella spp0 (0.0)3 (33.3)0 (0.0)3 (33.3)3 (33.3)Proteus spp0 (0.0)1 (16.7)0 (0.0)5 (83.3)0 (0.0) Pseudomonas aeruginosa 0 (0.0)0 (0.0)0 (0.0)3 (60.0)2 (40.0) Salmonella Typhi 9 (16.1)0 (0.0)23 (41.1)2 (3.6)22 (39.3) Salmonella Typhimurium 0 (0.0)0 (0.0)1 (100)0 (0.0)0 (0.0)Salmonella spp0 (0.0)0 (0.0)1 (100)0 (0.0)0 (0.0)Serratia spp0 (0.0)0 (0.0)0 (0.0)1 (100)0 (0.0)Shigella spp0 (0.0)0 (0.0)0 (0.0)0 (0.0)2 (100) Staphylococcus aureus 0 (0.0)10 (40.0)0 (0.0)5 (20.0)10 (40.0) Streptococcus pneumoniae 0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (100)Enterobacter spp0 (0.0)2 (66.7)0 (0.0)1 (33.3)0 (0.0)Total9 (5.7)22 (13.8)25 (15.7)54 (34.0)49 (30.8)Other diagnosis: diabetic foot ulcer, intestinal bacterial infection, urethral discharge syndrome, Abscess, Bacterial intestinal infection, Candidiasis, Celulitis, Cystitis, Diabetic foot ulcer, Osteomyelitis, Peptic ulcer, Peritonitis, Pneumonia, Post laparotomy, Pyomyocitis, Ulcerative colitis, acute respiratory infection, allergic rhinitis, acne atopic dermatitis, atypical pneumonia, enterocutaneous fistula, gastroenteritis, impetigo, shigellosis, worm infection Table 7Proportions of isolated bacteria with different diagnoses at Bukoba RRH, X²=161.34, P ≤ 0.001Bacteria isolatedDiagnosisAmoebiasisSeptic woundTyphoidUrinary Tract Infection (UTI)Other diagnosisAcinetobacter spp0 (0.0)1 (100)0 (0.0)0 (0.0)0 (0.0)Citrobacter spp0 (0.0)2 (33.3)0 (0.0)3 (50.0)1 (16.7) Escherichia coli 0 (0.0)3 (7.1)0 (0.0)31 (73.8)8 (19.1)Klebsiella spp0 (0.0)3 (33.3)0 (0.0)3 (33.3)3 (33.3)Proteus spp0 (0.0)1 (16.7)0 (0.0)5 (83.3)0 (0.0) Pseudomonas aeruginosa 0 (0.0)0 (0.0)0 (0.0)3 (60.0)2 (40.0) Salmonella Typhi 9 (16.1)0 (0.0)23 (41.1)2 (3.6)22 (39.3) Salmonella Typhimurium 0 (0.0)0 (0.0)1 (100)0 (0.0)0 (0.0)Salmonella spp0 (0.0)0 (0.0)1 (100)0 (0.0)0 (0.0)Serratia spp0 (0.0)0 (0.0)0 (0.0)1 (100)0 (0.0)Shigella spp0 (0.0)0 (0.0)0 (0.0)0 (0.0)2 (100) Staphylococcus aureus 0 (0.0)10 (40.0)0 (0.0)5 (20.0)10 (40.0) Streptococcus pneumoniae 0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (100)Enterobacter spp0 (0.0)2 (66.7)0 (0.0)1 (33.3)0 (0.0)Total9 (5.7)22 (13.8)25 (15.7)54 (34.0)49 (30.8)Other diagnosis: diabetic foot ulcer, intestinal bacterial infection, urethral discharge syndrome, Abscess, Bacterial intestinal infection, Candidiasis, Celulitis, Cystitis, Diabetic foot ulcer, Osteomyelitis, Peptic ulcer, Peritonitis, Pneumonia, Post laparotomy, Pyomyocitis, Ulcerative colitis, acute respiratory infection, allergic rhinitis, acne atopic dermatitis, atypical pneumonia, enterocutaneous fistula, gastroenteritis, impetigo, shigellosis, worm infection Proportions of isolated bacteria with different diagnoses at Bukoba RRH, X²=161.34, P ≤ 0.001 Other diagnosis: diabetic foot ulcer, intestinal bacterial infection, urethral discharge syndrome, Abscess, Bacterial intestinal infection, Candidiasis, Celulitis, Cystitis, Diabetic foot ulcer, Osteomyelitis, Peptic ulcer, Peritonitis, Pneumonia, Post laparotomy, Pyomyocitis, Ulcerative colitis, acute respiratory infection, allergic rhinitis, acne atopic dermatitis, atypical pneumonia, enterocutaneous fistula, gastroenteritis, impetigo, shigellosis, worm infection The Fig. 2 demonstrates high resistance levels among Gram-negative isolates, particularly to Ampicillin (AMP), Azithromycin (AZM), Ceftriaxone (CRO), and Tetracycline (TCY). Fig. 2Heat map of MDR resistance patterns for bacteria isolated at Bukoba RRH Heat map of MDR resistance patterns for bacteria isolated at Bukoba RRH Discussion This study demonstrates a substantial burden of antimicrobial resistance (AMR) among commonly isolated bacterial pathogens at our facility. The high proportion of resistance to frequently prescribed first-line antimicrobial agents indicates that empirical treatment practices may no longer be reliably effective in this setting. Clinically, this suggests an increased risk of treatment failure, prolonged illness, extended hospital stays, and higher healthcare costs. From a systems perspective, these findings reflect ongoing selective pressure driven by antibiotic overuse, misuse, and suboptimal stewardship enforcement. This study provides important insights into the antimicrobial resistance (AMR) patterns of bacterial isolates obtained from patients attending Bukoba Regional Referral Hospital (BRRH) between 2019 and 2023. The absence of bacterial isolates in 2021, as shown in Fig. 1, may be explained by interruptions in microbiology laboratory services following the breakdown of the laboratory incubator during that period. In addition, the procurement process for replacement equipment and laboratory supplies took a long time to complete, resulting in reduced culture processing and antimicrobial susceptibility testing activities. Consequently, fewer specimens were processed and reported in 2021, which affected the continuity of AMR surveillance data at Bukoba RRH. The culture positivity rate of 17.7% observed in this study is within the range reported in similar hospital-based studies across sub-Saharan Africa, where positivity rates typically range from 15 to 25% [23, 24]. The predominance of E. coli in urine samples aligns with its well-documented role as the leading cause of urinary tract infections (UTIs) in both community and hospital settings [24]. Similarly, Staphylococcus aureus was the most common pathogen isolated from pus, reflecting its importance in wound and soft tissue infections [6]. The predominance of Salmonella Typhi in stool specimens underscores the continuing burden of typhoid fever in the Kagera region and highlights sanitation and water safety challenges [18]. A key finding from this study is the alarmingly high level of resistance to first-line and commonly prescribed antimicrobial agents. E. coli exhibited over 80% resistance to ampicillin and over 90% to azithromycin. These findings are consistent with data from other Tanzanian tertiary hospitals, where widespread resistance to beta-lactams and macrolides has been reported [19, 23]. Similarly, S. aureus and coagulase-negative staphylococci (CoNS) demonstrated near-total resistance to penicillin, a trend widely documented across Africa and attributed to the production of beta-lactamase enzymes [17]. The persistence of such high resistance rates suggests irrational prescribing, over-the-counter availability of antimicrobial agents, and poor adherence to antimicrobial stewardship (AMS) principles [12, 25]. The distribution of resistant pathogens across different specimen types (e.g., blood, urine, wound swabs) also highlights the hospital as a potential reservoir for resistant organisms. This raises concerns regarding infection prevention and control (IPC) practices, including hand hygiene compliance, environmental sanitation, antimicrobial prophylaxis practices, and adherence to isolation protocols. High resistance rates in hospital-acquired infections suggest that both antimicrobial pressure and intra-facility transmission may be contributing factors. Carbapenems and nitrofurantoin retained significant activity against several resistant strains, indicating their role as effective options against multidrug-resistant (MDR) pathogens. However, reliance on carbapenems poses sustainability concerns, given their high cost and limited accessibility in many regional hospitals [17, 26]. Furthermore, increasing use of carbapenems without robust stewardship programs risks the emergence of carbapenem-resistant Enterobacteriaceae (CRE), a phenomenon already observed in other Tanzanian and African hospitals [18, 19]. The frequent occurrence of MDR isolates in this study is particularly concerning. MDR infections are associated with poor clinical outcomes, longer hospital stays, and increased treatment costs [5]. The findings echo the global concern that without urgent interventions, common infections may become untreatable, thereby reversing decades of medical progress [27]. Of additional concern is the mismatch between culture results, antibiotic prescriptions and diagnosis, especially for amoebiasis, with some patients receiving antimicrobial agents to which pathogens were resistant and 17.4% of patients not receiving any antibiotic therapy despite positive culture results. This misalignment points to critical gaps in diagnostic stewardship, clinician-laboratory communication, and the availability of laboratory results to guide prescribing practices [12, 25]. The findings of this study must be interpreted in the broader context of Tanzania’s National Action Plan on AMR, which emphasizes the establishment of AMS programs, strengthening of infection prevention and control (IPC), and integration of facilities into the national AMR surveillance system [1]. In high-income countries, robust surveillance systems have successfully reduced healthcare-associated infections by up to 30% [13], and similar gains could be made in Tanzania if AMS and IPC strategies are fully implemented. For example, Nigeria demonstrated a reduction in healthcare-associated infections following the introduction of effective infection control programs [28]. These examples highlight the potential benefits of implementing evidence-based interventions at BRRH and similar facilities. In summary, this study adds to the growing body of evidence that AMR is a critical challenge in Tanzania. It highlights the need for urgent action, including the development of facility-specific antibiograms, strict enforcement of rational antibiotic use policies, routine training of healthcare providers on AMS, and improvement of IPC practices to reduce the transmission of resistant pathogens. Without these measures, the effectiveness of available antimicrobial agents will continue to erode, threatening patient outcomes and healthcare system sustainability. Conclusions This study demonstrated a high burden of antimicrobial resistance and multidrug-resistant bacterial isolates among clinical specimens processed at Bukoba Regional Referral Hospital between 2019 and 2023. Gram-negative bacteria, particularly Escherichia coli and Klebsiella spp, showed high resistance to commonly prescribed antibiotics, highlighting challenges in empirical treatment and antimicrobial stewardship. Operational challenges, including interruptions in microbiology laboratory services in 2021, also affected AMR surveillance activities. These findings emphasize the need for strengthened laboratory capacity, routine culture and susceptibility testing, and improved utilization of AST results to support rational antimicrobial use and control the spread of AMR. Without immediate, facility-level interventions, the current resistance trends are likely to increase treatment failure, prolong hospital stays, escalate healthcare costs, and contribute to preventable morbidity and mortality. Strengths and limitations of the study This study provides facility-specific antimicrobial resistance data that can directly inform empirical treatment guidelines and antimicrobial stewardship efforts. The use of laboratory-confirmed culture and susceptibility results enhances the reliability and clinical relevance of the findings. The study was conducted at a single referral hospital, which may limit generalizability to other settings. Incomplete clinical data and the absence of molecular resistance testing may have restricted deeper analysis of resistance mechanisms and risk factors.